Praluent Sales to Resume as Sanofi, Regeneron Win New Infringement Trial

, Delaware Business Court Insider

   | 0 Comments

A federal appeals court on Thursday ordered a new trial in a high-profile patent infringement dispute over Sanofi's drug Praluent and lifted a permanent injunction barring sales of the biologic, used to fight high cholesterol.

This premium content is reserved for Delaware Business Court Insider subscribers.

Continue reading by getting started with a subscription.

Already a subscriber? Log in now

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article #1202800191583

Thank you!

This article's comments will be reviewed.